Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial autolysins are endogenous peptidoglycan hydrolases that play a critical role in cell wall maintenance, including cell wall turnover, cell division, and the separation of daughter cells. These enzymes cleave the covalent bonds within the peptidoglycan matrix, allowing the insertion of new cell wall material during growth. Beyond structural maintenance, autolysins act as virulence factors by facilitating biofilm formation, bacterial adhesion to host tissues, and the release of extracellular DNA. Because of their essential role in bacterial viability and pathogenesis, autolysins are highly attractive therapeutic targets. Traditional bactericidal antibiotics, such as penicillins and vancomycin, exert their effects in part by triggering uncontrolled autolysin activity, leading to bacterial self-destruction. Newer therapeutic strategies focus on directly inhibiting autolysins using novel glycopeptides like complestatin and corbomycin, which bind peptidoglycan to block autolysin access, or utilizing recombinant autolysins as direct enzybiotics to lyse drug-resistant strains.
Antibiotics like penicillins and vancomycin induce bacterial autolysis by activating or derepressing autolysins, leading to cell wall degradation and cell death. Conversely, type V glycopeptide antibiotics like complestatin and corbomycin bind directly to peptidoglycan, physically blocking autolysins from accessing and remodeling the cell wall, which traps the bacteria and prevents division. Recombinant autolysins (enzybiotics) can also be administered exogenously to directly digest the bacterial cell wall.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial autolysin (ATL).